Featured Research

from universities, journals, and other organizations

Three esophageal cancer cell lines commonly used in research prove to be from other cancers

Date:
January 20, 2010
Source:
Journal of the National Cancer Institute
Summary:
Three frequently used human esophageal adenocarcinoma cell lines used for research were confirmed as being from other tumor types. Two of the cell lines have been used in 11 US patents and more than 100 published studies.

Three frequently used human esophageal adenocarcinoma cell lines used for research were confirmed as being from other tumor types, according to a brief communication published online January 14 in the Journal of the National Cancer Institute. Two of the cell lines have been used in 11 U.S. patents and more than 100 published studies.

Related Articles


The 13 established esophageal adenocarcinoma cell lines are important because of the limited availability of patient samples and animal models.

To determine the authenticity of all the available cell lines, Winand N.M. Dinjens, Ph.D., Department of Pathology, Erasmus MC, University Medical Center, in Rotterdam, the Netherlands, and colleagues used data from pathology archives and genotyping assays in collaboration with the primary investigators who established the cell lines.

Cell lines SEG-1, BIC-1, and SK-GT-5 were proven to be cell lines from other tumor types, including lung carcinoma, colorectal adenocarcinoma, and gastric fundus carcinoma, respectively.

"Experimental results based on these contaminated cell lines have led to ongoing clinical trials recruiting [esophageal adenocarcinoma] patients, to more than 100 scientific publications, and to at least three National Institutes of Health cancer research grants and 11 U.S. patents, which emphasizes the importance of our findings," the authors write. "Widespread use of contaminated cell lines threatens the development of treatment strategies for [esophageal adenocarcinoma]."

The cell lines whose authenticity was verified will be placed in public repositories to promote future research, according to the brief communication.

The researchers also suggest that the clinical trial involving Barrett-related esophageal adenocarcinoma patients on the drug sorafenib should be reconsidered since the wrong cell line was used. They say there is now scant evidence for inhibition of the mitogen-activated protein kinase pathway by the drug in this cancer.

In an accompanying editorial, Robert Shoemaker, Ph.D., of the National Cancer Institute at Frederick in Maryland, questions this suggestion, pointing out that tissue of origin may not be important for all research studies. "…Given the knowledge that cancer is a heterogeneous disease," he writes, "one might question the rationale for any therapeutic maneuver that is based on studies conducted on a single cell line."

Shoemaker suggests that a study conducted with the correct cell lines (esophageal adenocarcinomas) would probably provide the same rationale for sorafenib because alterations in mitogen-activated protein kinase pathways are common in many tumor types.


Story Source:

The above story is based on materials provided by Journal of the National Cancer Institute. Note: Materials may be edited for content and length.


Cite This Page:

Journal of the National Cancer Institute. "Three esophageal cancer cell lines commonly used in research prove to be from other cancers." ScienceDaily. ScienceDaily, 20 January 2010. <www.sciencedaily.com/releases/2010/01/100114162243.htm>.
Journal of the National Cancer Institute. (2010, January 20). Three esophageal cancer cell lines commonly used in research prove to be from other cancers. ScienceDaily. Retrieved March 31, 2015 from www.sciencedaily.com/releases/2010/01/100114162243.htm
Journal of the National Cancer Institute. "Three esophageal cancer cell lines commonly used in research prove to be from other cancers." ScienceDaily. www.sciencedaily.com/releases/2010/01/100114162243.htm (accessed March 31, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Tuesday, March 31, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Soda, Salt and Sugar: The Next Generation of Taxes

Soda, Salt and Sugar: The Next Generation of Taxes

Washington Post (Mar. 30, 2015) — Denisa Livingston, a health advocate for the Dinι Community Advocacy Alliance, and the Post&apos;s Abby Phillip discuss efforts around the country to make unhealthy food choices hurt your wallet as much as your waistline. Video provided by Washington Post
Powered by NewsLook.com
UnitedHealth Buys Catamaran

UnitedHealth Buys Catamaran

Reuters - Business Video Online (Mar. 30, 2015) — The $12.8 billion merger will combine the U.S.&apos; third and fourth largest pharmacy benefit managers. Analysts say smaller PBMs could also merge. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
S. Leone in New Anti-Ebola Lockdown

S. Leone in New Anti-Ebola Lockdown

AFP (Mar. 28, 2015) — Sierra Leone imposed a three-day nationwide lockdown Friday for the second time in six months in a bid to prevent a resurgence of the deadly Ebola virus. Duration: 01:17 Video provided by AFP
Powered by NewsLook.com
These Popular Antibiotics Can Cause Permanent Nerve Damage

These Popular Antibiotics Can Cause Permanent Nerve Damage

Newsy (Mar. 27, 2015) — A popular class of antibiotic can leave patients in severe pain and even result in permanent nerve damage. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins